Navigation Links
HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic alliance with the Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The alliance will unite the strength and resources of both parties to accelerate the development of China's biomedical innovation and industrialization.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

TJAB, a state of the art pharmaceutical research & development platform, was jointly established by the Ministry of Science and Technology, the Ministry of Commerce, the Ministry of Health, the State Food and Drug Administration, and Tianjin Municipality.  It was established with the vision of creating China's International Innovation Zone of Biotechnology and Medicine (BioMed Zone) to boost China's biomedical industry. Situated at the heart of the Tianjin Binhai New Area, TJAB  has attracted more than 100 research & development groups, focusing in the areas of infectious diseases, cancer, diabetes, and hypertension.

Under the agreement, TJAB and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by enterprises residing in TJAB. HUYA will also be able to globalize select programs from TJAB through HUYA's innovative co-development model and worldwide pharmaceutical partners.

"TJAB attracts the most promising drug candidates from China and are known to play an important role in promoting novel Chinese drugs to international markets," said Clement Gingras, HUYA's CTO and COO, China. "Collectively, HUYA and TJAB will become a Mecca for drug innovation in China's biomedical sector."

Dr. Zeqi Zhou, Senior Vice President of TJAB, commented, "TJAB aims to become a leading innovation source for the biopharmaceutical industry in China. With HUYA's expertise in guiding China's novel drug development to international standards, this alliance will further promote TJAB's ability to attract top talents and become a world-class core technology platform for new drug development."


HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at


TJAB is located at the center of the BioMed Zone in the Binhai New Area, Tianjin. The Tianjin Binhai New Area is featured as the third economic growth hotspot in China, following the footsteps of Shenzhen and Shanghai Pudong. With 1.1 billion Yuan (RMB) of investment, this institute has a construction area of 350,000 square meters. The first 70,000 square meters building was ready to use in June 2009. More than 97 leading companies resided in the Academy, with over 100 proprietary projects (foreign projects accounted for approximately 60%) in incubation. Many of these projects are affiliated with the most prestigious universities in China. For more information, please visit  


Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International

Ping Yang, MS
Business Development Manager
HUYA Bioscience International

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Pixel Film Studios ... media panels to choose from, the possibilities are endless. Users have full control over ... the ProPanel: Pulse masking effects, users are sure to get heads to turn. , ...
(Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
Breaking Medicine News(10 mins):